SEC For	rm 4																			
FORM 4 UNITED STA				TES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549												OMB APPROVAL				
Section 16. Form 4 or Form 5 obligations may continue. See					ed purs	AT OF CHANGES IN BENEFICIAL OWNER d pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940									ΗP	Estin		er: verage burde sponse:	3235-0287 en 0.5	
1. Name and Address of Reporting Person [*] Burgess Paul D.						2. Issuer Name and Ticker or Trading Symbol <u>Cerevel Therapeutics Holdings, Inc.</u> [CERE]									k all applic Director	able)	ng Pers	son(s) to Iss 10% O Other (vner	
(Last) (First) (Middle C/O CEREVEL THERAPEUTICS HOLD				ЗS,		3. Date of Earliest Transaction (Month/Day/Year) 01/19/2024								Х	below)	See F	Remar	below) ks		
INC. 222 JACOBS STREET, SUITE 200 (Street)					4. lf	4. If Amendment, Date of Original Filed (Month/Day/Year)									 Individual or Joint/Group Filing (Check Applicable ine) X Form filed by One Reporting Person Form filed by More than One Reporting Person 					
CAMBRIDGE MA 02141 (City) (State) (Zip)					. Ru	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.														
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transa Date (Month/D				action	ar)	3.	ion str.	r. 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s)		nt of s ally ollowing l ion(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)				
									uired, Dis	spo	osed of,			ly C	(Instr. 3 a Owned	und 4)				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)) if any		4. Transac Code (I 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amour of Securities Underlying Derivative Securit (Instr. 3 and 4)		Derivative Security		9. Numbe derivativ Securitie Beneficia Owned Followin Reported Transact (Instr. 4)	e s ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable		Expiration Date	Title	Amour or Numbe of Shares	r						

Explanation of Responses:

(1)

1. The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each of January 19, 2025, January 19, 2026, January 19, 2027 and January 19, 2028, subject to the Reporting Person's continued service on each such vesting date.

(1)

Remarks:

Restricted

Stock Units

Title: Chief Business Development and Strategic Operations Officer

01/19/2024

/s/ Mark Bodenrader, as Attorney-in-Fact

81,065

\$0.00

(1)

Common

Stock

01/23/2024

81,065

D

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

A

(A)

81,065

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.